Seroconversion to Lutzomyia intermedia LinB-13 as a biomarker for developing cutaneous leishmaniasis

Area of Science:

• Medical Entomology
• Immunology
• Parasitology

Background:

• Sand fly saliva contains proteins that elicit host immune responses.
• Anti-saliva antibodies can indicate exposure to Leishmania vectors.
• Identifying reliable biomarkers for vector exposure is crucial for disease management.

Purpose of the Study:

• To identify and validate salivary proteins from Lutzomyia intermedia as biomarkers of exposure.
• To evaluate the potential of these biomarkers in predicting the development of cutaneous leishmaniasis (CL).

Main Methods:

• Expression of recombinant salivary proteins from Lutzomyia intermedia.
• Serological evaluation of antibody responses in individuals exposed to sand flies.
• Correlation analysis between antibody levels and exposure to Leishmania vectors.
• Longitudinal follow-up of a cohort to assess predictive value for CL development.

Main Results:

• Recombinant salivary protein rLinB-13 demonstrated high seroreactivity and accuracy in identifying exposure to Lutzomyia intermedia.
• IgG4 was the predominant antibody subclass against rLinB-13.
• Antibodies to rLinB-13 did not cross-react with salivary proteins from Lu. longipalpis.
• Individuals who developed CL showed higher anti-rLinB-13 IgG responses prior to symptom onset and lower delayed-type hypersensitivity (DTH) responses.

Conclusions:

• Recombinant LinB-13 is a highly accurate biomarker for Lutzomyia intermedia exposure.
• Seroconversion to rLinB-13 is a marker of risk for developing CL caused by Leishmania braziliensis.
• Developing diagnostic tools based on vector salivary molecules offers a promising strategy for disease management.